Manabu Morimoto
Overview
Explore the profile of Manabu Morimoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
2524
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hamaguchi T, Ueno M, Kobayashi S, Tezuka S, Morimoto M, Kato T, et al.
Case Rep Gastroenterol
. 2025 Feb;
19(1):14-21.
PMID: 39981166
Introduction: We report the case of a man in his 50s with stage IVB non-small cell lung cancer who developed severe immune-related hepatitis caused by pembrolizumab. Case Presentation: He received...
2.
Endo K, Miwa H, Sugimori K, Shibasaki K, Yonei S, Ishino Y, et al.
Diagnostics (Basel)
. 2025 Jan;
15(2).
PMID: 39857080
Detective flow imaging (DFI) endoscopic ultrasonography (EUS) can identify the microvascular flow imaging of a mural nodule (MN) in an intraductal papillary mucinous neoplasm (IPMN) without the use of contrast...
3.
Nagashima S, Kobayashi S, Tsunoda S, Yamachika Y, Tozuka Y, Fukushima T, et al.
Clin J Gastroenterol
. 2024 Dec;
18(1):125-129.
PMID: 39616585
Cabozantinib is a multi-kinase inhibitor targeting multiple tyrosine kinases. It improves overall survival and progression-free survival in patients previously treated with sorafenib for advanced hepatocellular carcinoma (HCC) compared to the...
4.
Chuma M, Uojima H, Toyoda H, Hiraoka A, Arase Y, Atsukawa M, et al.
Hepatol Int
. 2024 Jul;
18(5):1472-1485.
PMID: 38963640
Background: The aims of this study were to identify clinically significant biomarkers of a response to atezolizumab plus bevacizumab (ATZ + BV) therapy and to develop target strategies against unresectable...
5.
Zhang Y, Numata K, Imajo K, Uojima H, Funaoka A, Komiyama S, et al.
Hepatol Res
. 2024 Jul;
54(12):1174-1192.
PMID: 38953838
Aim: This study aims to evaluate the efficacy and safety of lenvatinib radiofrequency ablation (RFA) sequential therapy for certain hepatocellular carcinoma (HCC) patients. Methods: One hundred and nineteen patients with...
6.
Ikeda M, Yamashita T, Ogasawara S, Kudo M, Inaba Y, Morimoto M, et al.
Liver Cancer
. 2024 May;
13(2):193-202.
PMID: 38751550
Introduction: Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher antitumor activity is expected for the combination treatment. The aim...
7.
Kobayashi S, Fukushima T, Ueno M, Chuma M, Numata K, Tsuruya K, et al.
Liver Int
. 2024 Mar;
44(6):1343-1350.
PMID: 38436529
Background: Although the combination of atezolizumab and bevacizumab (ATZ + BEV) is a standard treatment for advanced hepatocellular carcinoma (HCC), strategies for addressing treatment failure and prognostic factors of post-progression...
8.
Nagashima S, Kobayashi S, Tsunoda S, Yamachika Y, Tozuka Y, Fukushima T, et al.
Int J Clin Oncol
. 2023 Nov;
29(2):188-194.
PMID: 37991558
Background: The global phase 3 NAPOLI -1 trial of patients with pancreatic ductal adenocarcinoma (PDAC) demonstrated an overall survival (OS) benefit from using liposomal irinotecan and 5-fluorouracil/leucovorin (nal-IRI + 5-FU/LV)...
9.
Murakawa M, Kawahara S, Takahashi D, Kamioka Y, Yamamoto N, Kobayashi S, et al.
World J Surg Oncol
. 2023 Aug;
21(1):263.
PMID: 37620940
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, and surgical resection is the only potentially curative approach. However, the rate of recurrence remains high, particularly within...
10.
Uojima H, Chuma M, Hidaka H, Tsuda T, Kobayashi S, Hattori N, et al.
Eur J Gastroenterol Hepatol
. 2023 Jul;
35(8):865-873.
PMID: 37395239
Objective: To investigate the association between body composition and prognosis in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Methods: This cohort study analysed 119 patients who received...